181 related articles for article (PubMed ID: 14585912)
1. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes.
MacDonald TM; Pettitt D; Lee FH; Schwartz JS
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii3-10. PubMed ID: 14585912
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Layton D; Hughes K; Harris S; Shakir SA
Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
[TBL] [Abstract][Full Text] [Related]
4. Meloxicam: selective COX-2 inhibition in clinical practice.
Furst DE
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
[TBL] [Abstract][Full Text] [Related]
5. Ischaemic colitis in a patient taking meloxicam.
Garcia B; Ramaholimihaso F; Diebold MD; Cadiot G; Thiéfin G
Lancet; 2001 Mar; 357(9257):690. PubMed ID: 11247558
[TBL] [Abstract][Full Text] [Related]
6. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
7. [Rheumatic disease therapy without regret. Meloxicam dosage safety].
MMW Fortschr Med; 2002 Nov; 144(46):66-7. PubMed ID: 12534086
[No Abstract] [Full Text] [Related]
8. Application of a propensity score to adjust for channelling bias with NSAIDs.
Morant SV; Pettitt D; MacDonald TM; Burke TA; Goldstein JL
Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):345-53. PubMed ID: 15170763
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Dequeker J; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):937-45. PubMed ID: 9783757
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events and COX-2 inhibitors.
Haldey EJ; Pappagallo M
JAMA; 2001 Dec; 286(22):2809-10; author reply 2811-2. PubMed ID: 11735745
[No Abstract] [Full Text] [Related]
11. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
Lee MC; Lee S; Suh DC; Kim J; Kong SX;
Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with cyclooxygenase-2 inhibitors.
Lanas A
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
Schoenfeld P
Am J Med; 1999 Dec; 107(6A):48S-54S. PubMed ID: 10628593
[TBL] [Abstract][Full Text] [Related]
16. Meloxicam--a safer NSAID?
Drug Ther Bull; 1998 Aug; 36(8):62-4. PubMed ID: 9876404
[No Abstract] [Full Text] [Related]
17. [Selective cyclooxygenase-2 inhibitor].
Hettich M; Thomae K
Internist (Berl); 1997 Oct; 38(10):1007. PubMed ID: 9432492
[No Abstract] [Full Text] [Related]
18. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
[TBL] [Abstract][Full Text] [Related]
19. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
MacDonald TM; Morant SV; Goldstein JL; Burke TA; Pettitt D
Gut; 2003 Sep; 52(9):1265-70. PubMed ID: 12912856
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase inhibition: between the devil and the deep blue sea.
Hawkey CJ
Gut; 2002 May; 50 Suppl 3(Suppl 3):III25-30. PubMed ID: 11953329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]